BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised $20 million from a combination of equity capital and venture debt financing, more than doubling BiPar's cash resources. Participating in the round were existing equity investors Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners, along with venture-debt lender Lighthouse Capital Partners.
